Childhood cancer survival rates vary in different countries and ethnicities ([@bib34]; [@bib4]; [@bib16], [@bib17]; [@bib20]; [@bib1]; [@bib5]; [@bib21]). Nevertheless, international ([@bib16], [@bib17]; [@bib5]) and ethnic ([@bib34]; [@bib4]; [@bib20]; [@bib1]; [@bib21]) comparisons are relatively few, particularly with low-income countries, mainly because of the absence of data.

Survival comparisons between countries and ethnic groups are important to assess the magnitude of survival discrepancies and to examine the possible sources of variability. By comparing survival estimates of developing countries with those from developed nations along time periods, delay in achieving comparable survival levels can be quantified.

In this study, we provide up-to-date estimates of childhood leukaemia and lymphoma survival for the Philippine resident population and Asian Americans, who have similar ethnicity, and Asian Americans and Caucasians from the United States, who have the same health-care system. To quantify delay in survival and determine lag time, 5-year estimates for various time periods between 1976--1980 and 2001--2005 were computed for children in the United States, and compared with the 2001--2005 survival estimates for Philippine residents.

Materials and methods
=====================

US data were abstracted from the database of the [@bib35] Program Limited-Use Data (1973--2005) (SEER, 2008), which routinely collects data on cancer patients from selected populations in the United States. For this analysis, the SEER 9 and 17 databases were used. From the SEER 17 database, patients 0--14 years of age, of either Asian-American or Caucasian origin, diagnosed with leukaemia or lymphoma based on the International Classification of Childhood Cancer (ICCC) definition ([@bib33]) between 1 January 1996 and 31 December 2005 were included. Death certificate only (DCO), *in situ* and autopsy cases were excluded. A total of 625 Asian-American and 6834 Caucasian children were included, comprising of 496 (79%) leukaemia and 129 (21%) lymphoma cases from the former, and 5344 (78%) leukaemia and 1490 (22%) lymphoma cases, from the latter group. In this study, Filipino Americans were combined with other Asian-American groups, because of their small numbers. From the SEER 9 database, patients 0--14 years of age, regardless of race, and diagnosed with ICCC classified leukaemia or lymphoma between 1 January 1976 and 31 December 2005 were included. DCO, *in situ* and autopsy cases were likewise excluded, leaving 6913 leukaemia and 2253 lymphoma cases for the analysis.

The databases used in the analyses of the Philippine resident population came from the Philippine Cancer Society--Manila Cancer Registry (PCS--MCR) and the Department of Health--Rizal Cancer Registry (DOH--RCR). These registries cover the National Capital Region (NCR), more commonly known as Metro Manila, which is the largest urban metropolis, and the political, social, educational and economic centre. This population is wealthier and has better access to health-care and cancer diagnostic and treatment facilities than the rest of the country ([@bib25]). The Philippine registries follow the cancer registration definitions and data collection guidelines set by the International Agency for Research on Cancer and the International Association of Cancer Registries. They are regarded as among the high-quality cancer registries from developing countries and have been regularly included in Cancer Incidence in Five Continents ([@bib23]; [@bib26], [@bib27], [@bib28]; [@bib13]).

From a list of patients diagnosed between 1 January 1996 and 31 December 2005, subjects were selected using the same inclusion and exclusion criteria as for the SEER 17 database. Survival status was assessed from death certificate notifications mentioning cancer as the cause of death, which were collected from the Local Civil Registry Offices. For those not identified as dead, active follow-up by personal visits to the patients or their families in the last known place of residence was used to confirm vital status.

From the 1500 childhood leukaemia and lymphoma cases registered in the PCS--MCR and DOH--RCR databases, 4 (\<1%) were excluded because of invalid data, and 232 (16%) because of missing follow-up information. A total of 1264 (84%) patients were left in the analysis, for whom anonymised data sets were prepared. Of the cases, 86% (1081) had leukaemia while the remaining 14% (183) had lymphoma.

The project proposal was approved by the ethics review board of the National Institutes of Health of the University of the Philippines Manila. The information obtained strictly conformed to the code of conduct stipulated by the Guidelines on Confidentiality for Population-Based Cancer Registries ([@bib19]).

Data analysis
-------------

In this study, period analysis of survival analysis was used ([@bib6]). With this approach, only the survival experience of patients for the 2001--2005 period was included. It has been shown that period analysis provides more up-to-date estimates of survival that closely predict survival later observed for patients diagnosed in the relevant period ([@bib10]; [@bib7], [@bib8]; [@bib36]; [@bib15]; [@bib32]). Analyses were carried out by types of leukaemia ((Ia) ALL, (Ib) acute myeloid (AML), and other types, including (Ic) chronic myeloproliferative diseases, (Id) myelodysplastic syndrome and other myeloproliferative diseases and (Ie) unspecified and other leukaemias) and lymphomas ((IIa) Hodgkins (HL), (IIb) non-Hodgkin (NHL), and other types, including (IIc) Burkitt, (IId) miscellaneous lymphoreticular neoplasms and (IIe) unspecified lymphomas) ([@bib33]), by sex and by age (\<1, 1--4, 5--9 and 10--14). Owing to small sample sizes for the other subtypes, only the survival estimates for ALL, AML and NHL were separately computed.

Estimates of relative survival (calculated as the ratio of observed and expected survival) were derived using the so-called Ederer II method ([@bib14]) and life tables for the year 2000. Owing to the absence of life tables for other races, the life table for whites from the US National Center for Health Statistics ([@bib2]) was used for both SEER populations. The life table for the Philippine resident population was derived from the projected population estimate and the actual mortality data for this area, obtained from the Philippine National Statistics Office. To compare overall survival estimates between the different cancer populations, age was adjusted using the distribution of the Filipinos patients. The age groups used were \<1, 1--4, 5--9 and 10--14.

To test for differences in survival between the ethnic groups, a novel modelling approach for period analysis ([@bib9]) was used. First, age-specific numbers of patients at risk and of deaths by year of follow-up were calculated separately for each population group. Then, Poisson regression models were fitted, in which the numbers of deaths were modelled as a function of the group (Philippine residents or Asian Americans or US Caucasians) and year of follow-up (1, 2, 3, 4, 5 -- entered as a categorical variable), using the logarithm of the person-years at risk as offset, and accounting for late entries and withdrawals as half persons, as described in detail elsewhere ([@bib9]). In models for all types of leukaemia and lymphoma (both sexes and separately for men and women), and for ALL, AML and NHL, we also included age groups. This approach allowed testing for significance of differences in survival, after accounting for differences in distribution of subgroups, based on *P*-values for the population parameter estimate. A significance level of =0.05 (two-sided testing) was used.

Using the SEER 9 database, period survival estimates for the years 1976--1980, 1981--1985, 1986--1990, 1991--1995, 1996--2000 and 2001--2005 were derived for children in the United States, using the same algorithms used for the Philippine residents, Asian Americans and US Caucasians. These survival estimates were then compared with those for the Philippine population in 2001--2005, using only the data from the SEER 9 registries, as these have information dating back to the early 1970s. The other SEER registries were only included in the programme in the 1990s and 2001 ([@bib24]).

Results
=======

In all three populations and in both sexes, a majority of leukaemia cases were diagnosed as ALL ([Table 1](#tbl1){ref-type="table"}), whereas NHL was the commonest lymphoma subtype. However, the proportion of leukaemia patients with ALL was lower, and of patients with undifferentiated leukaemias and AML was higher in the Philippine resident population than in the United States (*P*\<0.0001). Among lymphoma patients, the proportion of children with HL was lower, and the proportion of children with other types of lymphoma was larger in Philippine residents (*P*\<0.0001). More men were diagnosed than women in all groups for both types of malignancies. For leukaemias, the differences in age distribution between the three populations were not large ([Table 2](#tbl2){ref-type="table"}). For lymphomas, while most cases were older than 5 years in all groups, Philippine residents were relatively younger than the SEER populations, with a larger proportion (29.5%) of cases aged 4 years and below.

Age-adjusted, and type-, age- and sex-specific estimates of 5-year absolute and relative survival for the 2001--2005 period are shown in [Table 3](#tbl3){ref-type="table"}. Much lower leukaemia relative survival was observed in Filipinos living in the Philippines (32.9%) than in Asian Americans (80.1%) and Caucasians (81.9%). Children with ALL have better survival than those with AML for all populations, but this advantage is small among Philippine residents. Survival estimates for men are slightly higher than for women in all three groups. Stratification by age reveals that the survival disadvantage of Philippine residents is particularly large for age group 10--14 years, where 5-year relative survival was as low as 17.6%. For lymphoma, and NHL in particular, relative survival estimates for Philippine residents were likewise much lower (47.7 and 49.7%, for lymphoma and NHL, respectively) than the US populations (90.5 and 84.8% for Asian Americans, and 87.0 and 81.0% for Caucasians).

Trends in 5-year survival for childhood leukaemia and lymphoma cases in the United States between 1976--1980 and 2001--2005 is shown in [Table 4](#tbl4){ref-type="table"}. For all groups, rates strongly increased over time, with improvements between the 1976--1980 and 2001--2005 periods ranging from 25 to 40%. When compared with Philippine residents, survival estimates for patients from the Philippines in 2001--2005 were even lower than those for the US populations in 1976--1980, with the exception of AML, for which survival in the Philippines in 2001--2005 was similar to that for American children in 1981--1990.

Discussion
==========

In this comparative analysis of childhood leukaemia and lymphoma in 2001--2005, a strong survival disadvantage was observed for Philippine residents as compared with US children, while survival among Asian-American and Caucasian children was similar. Although estimates for Philippine children were expected to be lower than US patients, a lag in achievement of comparable survival rates of 20 to \>30 years is disappointing. These survival rates highlight the deficiencies of paediatric cancer care in the Philippines, including unavailability of and inadequate access to diagnostic and treatment facilities, financial difficulties and lack of awareness.

In the Philippines, while state-of-the-art diagnostic and treatment modalities, such as immunophenotyping, cytogenetics, linear accelerator, MRI and PET--CT scan are present, these are inaccessible to most of the population. Services are available in paediatric oncology sections of large tertiary hospitals, which are few, mainly situated in major cities, and sometimes understaffed. Although there are adequate numbers of paediatric haematologists or oncologists in the country, there is no certified paediatric cancer unit ([@bib31]). A majority of the institutes and hospitals do not have full time paediatric haematologists--oncologists and specialised paediatric oncology nurses ([@bib12]). Outside these units, diagnostic testing was described as nonexistent to limited, with a long wait for results at best, and availability of medications and blood products were limited or irregular, making supportive care for cancer patients poor ([@bib31]).

The expensive nature of paediatric cancer care further complicates the problem of inadequate health services and staff. The Philippines has a 2008 Gross National Income per capita of USD 3900 as compared with USD 46 970 for the United States ([@bib38]). Although a national health-care insurance, PhilHealth, was introduced in 1997, its coverage is limited and most patients are not enrolled. Moreover, most patients cannot start treatment, and for those who do, treatment abandonment is common. In contrast, almost all children with cancer in the United States are treated in highly specialised paediatric oncology centres, which are a part of a national children oncology group. Furthermore, a special insurance programme covering children with serious illnesses, including cancer, is available ([@bib11]), resulting in a lower frequency of treatment discontinuation.

Lack of awareness is an important issue in the Philippines, especially on health problems relating to children, which leads to delays in seeking medical help and treatment ([@bib37]). Owing to the nonspecificity of signs and symptoms of early childhood leukaemia and lymphoma, most patients from developing countries are diagnosed at a later stage. For example, data from the Philippine General Hospital show that 55.3% of newly diagnosed paediatric charity ALL cases diagnosed in 2003--2007 were high risk by US National Cancer Institute criteria, with more than half having an initial white blood cell count \>50 000 ([@bib22]). Furthermore, 71% of newly diagnosed solid tumour patients in 2008 presented at stages III and IV. Similarly, inadequate education and poverty compel some parents to turn to traditional and alternative medicines for treatment ([@bib37]; [@bib3]).

Similar survival estimates were observed between Asian Americans and Caucasians, consistent with previous findings ([@bib20]). This could be attributed to the high level of health-care access among Asian Americans, the majority of whom being either native born (31%) or naturalised citizens (34%) ([@bib30]). Moreover, Asian Americans have higher earnings than the average American, with a large proportion having attained a bachelor\'s degree or more (44%), and more likely to be in management, professional or related occupations (45%) ([@bib30]).

Taken together, our results underline the overwhelming importance of access to effective treatment as accounting for the observed survival differences between the populations studied. Even though some ethnic variability has been observed, under trial conditions with identical treatment and access ([@bib1]), this variation was small compared with the huge variation according to the health-care system in our study.

Some limitations of our study are relevant because not all factors that could affect survival could be considered. Information not obtainable include factors related to cancer services, such as training and skills of health-care professionals, accuracy of diagnostic tests, chemotherapy protocols used, and disease characteristics such as cancer stage, and comorbidities. Furthermore, in spite of exhaustive measures to locate Philippine resident for survival information, including personal visits to the homes, follow-up was in complete for 25% of patients, attributable to the high migration and mobility in the study area. Nevertheless, it can be assumed that patients lost to follow-up have not received or have discontinued treatment, as follow-up information was not found or incomplete in hospitals within the NCR. The availability of cancer treatment is limited in the surrounding regions and it is unlikely that patients lost to follow-up have higher survival than those who were not.

In spite of these limitations, our results highlight the very large survival disadvantage of children in the Philippines. Efforts such as more twinning programmes between hospitals and specialised centres in developed and developing countries should be considered, as well as increased government spending on health, which have been shown to be effective in enhancing care of childhood leukaemia in developing countries ([@bib29]; [@bib18]).
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###### Tumour characteristics of childhood leukaemia and lymphoma patients among the Philippine resident population and Asian Americans and Caucasians from US SEER, 1996--2005

                              **Philippine resident population**   **Asian American**   **Caucasians**                        
  ------------ -------------- ------------------------------------ -------------------- ---------------- ------ ------ ------ ----------
  Both sexes   *Leukaemia*    1081                                                      496                     5344          \<0.0001
                ALL           699                                  64.7                 376              75.8   4350   81.4    
                AML           252                                  23.3                 93               18.8   789    14.8    
                Other types   130                                  12.0                 27               5.4    205    3.8     
               *Lymphoma*     183                                                       129                     1490          \<0.0001
                HL            21                                   11.5                 34               26.4   607    40.7    
                NHL           85                                   46.5                 65               50.4   607    40.7    
                Other types   77                                   42.1                 30               23.3   276    18.5    
                                                                                                                               
  Males        *Leukaemia*    639                                                       285                     2963          \<0.0001
                ALL           429                                  67.1                 220              77.2   2417   81.6    
                AML           135                                  21.1                 51               17.9   426    14.4    
                Other types   75                                   11.7                 14               4.9    120    4.1     
               *Lymphoma*     120                                                       86                      963           \<0.0001
                HL            15                                   12.5                 23               26.7   353    36.7    
                NHL           59                                   49.2                 40               46.5   385    40.0    
                Other types   46                                   38.3                 23               26.7   225    23.4    
                                                                                                                               
  Females      *Leukaemia*    442                                                       211                     2381          \<0.0001
                ALL           270                                  61.1                 156              73.9   1933   81.2    
                AML           117                                  26.5                 42               19.9   363    15.3    
                Other types   55                                   12.4                 13               6.2    85     3.6     
               *Lymphoma*     63                                                        43                      527           \<0.0001
                HL            6                                    9.5                  11               25.6   254    48.2    
                NHL           26                                   41.3                 25               58.1   222    42.1    
                Other types   31                                   49.2                 7                16.3   51     9.7     

Abbreviations: ALL=acute lymphoblastic leukaemia; AML=acute myeloblastic leukaemia; HL=Hodgkin lymphoma; NHL=non-Hodgkin lymphoma; SEER=surveillance, epidemiology and end results.

###### Childhood leukaemia and lymphoma patients among the Philippine resident population and Asian Americans and Caucasians from US SEER, 1996--2005, by age group

                **Philippine resident population**   **Asian American**   **Caucasians**                        
  ------------- ------------------------------------ -------------------- ---------------- ------ ------ ------ ----------
  *Leukaemia*   1081                                                      496                     5344          0.009
   \<1          67                                   6.2                  34               6.9    319    6.0     
   1--4         457                                  42.3                 249              50.2   2527   47.3    
   5--9         349                                  32.3                 127              25.6   1455   27.2    
   10--14       208                                  19.2                 86               17.3   1043   19.5    
                                                                                                                 
  *ALL*         699                                                       376                     4350          \<0.001
   \<1          38                                   5.4                  18               4.8    142    3.3     
   1--4         315                                  45.1                 206              54.8   2211   50.8    
   5--9         234                                  33.5                 96               25.5   1241   28.5    
   10--14       112                                  16.0                 56               14.9   756    17.4    
                                                                                                                 
  *Lymphoma*    183                                                       129                     1490          \<0.0001
   \<1          2                                    1.1                  2                1.6    10     0.7     
   1--4         52                                   28.4                 26               20.2   190    12.8    
   5--9         52                                   28.4                 32               24.8   449    30.1    
   10--14       77                                   42.1                 69               53.5   841    56.4    

Abbrevaitions: ALL=acute lymphoblastic leukaemia; SEER=surveillance, epidemiology and end results.

###### Five-year survival (in %) of childhood leukaemia and lymphoma patients, Philippine resident population and Asian Americans and Caucasians from US SEER, 2001--2005

                                            **(1) Philippine resident population**   **Between (1) and (2)**   **(2) Asian American**   **Between (3) and (2)**   **(3) Caucasians**                                 
  ----------------------------------------- ---------------------------------------- ------------------------- ------------------------ ------------------------- -------------------- ------ ------ -------- ------ -----
  *Absolute survival*                                                                                                                                                                                                 
   Leukaemias                                                                                                                                                                                                         
    Overall[a](#t3-fn2){ref-type="fn"}      32.3                                     2.6                       47.7                     \<0.001                   80.0                 2.6    1.7    0.39     81.7   0.7
    By type[a](#t3-fn2){ref-type="fn"}                                                                                                                                                                                
     ALL                                    33.8                                     3.1                       53.3                     \<0.001                   87.2                 2.4    −1.1   0.9993   86.1   0.7
     AML                                    28.2                                     5.7                       33.5                     \<0.001                   61.8                 7.5    −2.0   0.86     59.7   2.5
    By sex[a](#t3-fn2){ref-type="fn"}                                                                                                                                                                                 
     Male                                   35.6                                     3.5                       46.3                     \<0.001                   81.9                 3.5    −0.6   0.83     81.2   1.0
     Female                                 27.3                                     3.8                       51.0                     \<0.001                   78.3                 3.8    3.8    0.12     82.1   1.1
    By age group                                                                                                                                                                                                      
     \<1                                    29.0                                     10.3                      31.5                     0.02                      60.5                 11.9   −3.0   0.72     57.4   3.7
     1--4                                   37.8                                     4.3                       44.2                     \<0.001                   82.0                 3.6    6.5    0.08     88.5   0.9
     5--9                                   34.7                                     4.5                       45.7                     \<0.001                   80.4                 5.0    1.9    0.43     82.3   1.4
     10--14                                 17.5                                     4.7                       63.8                     \<0.001                   81.3                 5.6    −7.6   0.53     73.7   1.9
                                                                                                                                                                                                                      
   Lymphomas                                                                                                                                                                                                          
    Both sexes[a](#t3-fn2){ref-type="fn"}   47.1                                     6.1                       43.2                     \<0.001                   90.3                 2.6    −3.5   0.99     86.9   1.4
    NHL[a](#t3-fn2){ref-type="fn"}          49.1                                     9.3                       35.6                     \<0.01                    84.7                 4.9    −3.9   0.85     80.8   2.1
                                                                                                                                                                                                                      
  *Relative survival*                                                                                                                                                                                                 
   Leukaemias                                                                                                                                                                                                         
    Overall[a](#t3-fn2){ref-type="fn"}      32.9                                     2.6                       47.3                     \<0.001                   80.1                 2.6    1.7    0.38     81.9   0.7
    By type[a](#t3-fn2){ref-type="fn"}                                                                                                                                                                                
     ALL                                    34.4                                     3.1                       52.9                     \<0.001                   87.3                 2.4    −1.1   0.995    86.2   0.7
     AML                                    28.5                                     5.7                       33.3                     \<0.001                   61.9                 7.5    −2.0   0.86     59.8   2.5
    By sex[a](#t3-fn2){ref-type="fn"}                                                                                                                                                                                 
     Male                                   36.2                                     3.6                       45.8                     \<0.001                   82.0                 3.5    −0.6   0.83     81.4   1.0
     Female                                 27.6                                     3.8                       50.8                     \<0.001                   78.4                 3.8    3.8    0.12     82.2   1.1
    By age group                                                                                                                                                                                                      
     \<1                                    30.3                                     10.7                      30.6                     \<0.001                   60.9                 12.0   −3.1   0.26     57.9   3.7
     1--4                                   38.7                                     4.4                       43.4                     \<0.001                   82.1                 3.6    6.5    0.43     88.6   0.9
     5--9                                   34.8                                     4.5                       45.6                     \<0.001                   80.4                 5.0    1.9    0.43     82.3   1.4
     10--14                                 17.6                                     4.7                       63.9                     \<0.001                   81.5                 5.6    −7.6   0.53     73.8   1.9
   Lymphomas                                                                                                                                                                                                          
    Both sexes[a](#t3-fn2){ref-type="fn"}   47.7                                     6.2                       42.7                     \<0.001                   90.5                 2.6    −3.5   0.98     87.0   1.4
    NHL[a](#t3-fn2){ref-type="fn"}          49.7                                     9.4                       35.1                     \<0.01                    84.8                 4.9    −3.8   0.85     81.0   2.2

Abbreviations: ALL=acute lymphoblastic leukaemia; AML=acute myeloblastic leukaemia; NHL=non-Hodgkin lymphoma; SEER=surveillance, epidemiology and end results.

Adjusted to the age distribution of the leukaemia/lymphoma of the patients from the Philippines.

###### Five-year survival (in %) of childhood leukaemia and lymphoma patients, US SEER 9, 1976--2005

                                            **1976--1980**   **1981--1985**   **1986--1990**   **1991--1995**   **1996--2000**   **2001--2005**                                    
  ----------------------------------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ------ ----- ------ ----- ------ -----
  *Absolute survival*                                                                                                                                                              
   Leukaemias                                                                                                                                                                       
    Overall[a](#t4-fn2){ref-type="fn"}      52.7             2.7              60.7             1.6              66.5             1.4              72.3   1.3   79.1   1.2   82.9   1.1
    By type[a](#t4-fn2){ref-type="fn"}                                                                                                                                              
     ALL                                    60.7             3.1              67.4             1.7              74.2             1.5              79.1   1.4   85.6   1.1   88.1   1.0
     AML                                    20.7             4.8              29.4             4.4              35.8             4.4              40.5   3.8   48.9   3.7   60.7   3.7
    By sex[a](#t4-fn2){ref-type="fn"}                                                                                                                                               
     Male                                   49.4             3.9              58.1             2.2              64.1             1.9              71.0   1.8   77.9   1.6   82.6   1.4
     Female                                 56.1             3.7              62.2             2.2              69.3             2.1              73.8   1.9   81.1   1.7   83.5   1.6
    By age group                                                                                                                                                                    
     \<1                                    8.7              10.5             28.0             6.3              27.0             5.2              46.2   6.5   52.0   6.5   64.1   5.5
     1--4                                   64.3             4.5              68.4             2.2              76.4             1.9              78.4   1.7   87.4   1.4   89.3   1.3
     5--9                                   53.2             5.0              67.3             3.0              72.2             2.7              74.4   2.4   82.0   2.1   83.6   2.0
     10--14                                 40.5             4.7              43.2             3.5              48.0             3.5              63.5   3.5   64.7   3.2   73.7   2.9
   Lymphomas                                                                                                                                                                        
    Both sexes[a](#t4-fn2){ref-type="fn"}   60.9             3.8              72.6             2.8              76.1             2.6              84.2   2.1   84.8   2.2   88.7   1.8
    NHL[a](#t4-fn2){ref-type="fn"}          54.4             6.1              65.4             4.4              75.0             3.8              74.4   3.8   81.7   3.2   84.5   2.6
                                                                                                                                                                                    
  *Relative survival*                                                                                                                                                              
   Leukaemias                                                                                                                                                                       
    Both sexes[a](#t4-fn2){ref-type="fn"}   52.8             2.8              60.8             1.6              66.6             1.4              72.4   1.3   79.2   1.2   83.0   1.1
    By type[a](#t4-fn2){ref-type="fn"}                                                                                                                                              
     ALL                                    60.8             3.1              67.5             1.7              74.3             1.5              79.2   1.4   85.7   1.2   88.2   1.0
     AML                                    20.7             4.8              29.5             4.4              35.8             4.4              40.5   3.8   49.0   3.7   60.8   3.7
    By sex[a](#t4-fn2){ref-type="fn"}                                                                                                                                               
     Male                                   49.5             3.9              58.2             2.2              64.2             1.2              71.1   1.8   78.1   1.6   82.7   1.4
     Female                                 56.2             3.7              62.3             2.2              69.4             2.1              73.9   1.9   81.2   1.7   83.6   1.6
    By age group                                                                                                                                                                    
     \<1                                    8.8              10.5             28.2             6.3              27.2             5.2              46.6   6.6   52.4   6.6   64.6   5.5
     1--4                                   64.4             4.5              68.5             2.2              76.5             1.9              78.5   1.7   87.6   1.4   89.4   1.3
     5--9                                   53.3             5.0              67.4             3.0              72.3             2.7              74.5   2.4   82.1   2.1   83.6   2.0
     10--14                                 40.6             4.7              43.2             3.5              48.1             3.5              63.6   3.5   64.8   3.2   73.9   2.9
   Lymphomas                                                                                                                                                                        
    Both sexes[a](#t4-fn2){ref-type="fn"}   61.0             3.8              72.7             2.8              76.2             2.6              84.3   2.1   84.9   2.2   88.8   1.8
    NHL[a](#t4-fn2){ref-type="fn"}          54.4             6.1              65.5             4.5              75.1             3.8              74.5   3.8   81.8   3.2   84.6   2.6

Abbreviations: ALL=acute lymphoblastic leukaemia; AML=acute myeloblastic leukaemia; NHL=non-Hodgkin lymphoma; SEER=surveillance, epidemiology and end results.

Adjusted to the age distribution of the leukemia/lymphoma of the patients from the Philippines.
